Direct answer
Heart disease care depends on the diagnosis. For common atherosclerotic disease, tobacco cessation, appropriate eating and activity, and prescribed blood-pressure and cholesterol treatment can reduce risk. After coronary events, eligible rehabilitation reduces heart attacks and admissions; short-term mortality benefit is uncertain. Supplements have selected marker or adjunct uses, with important evidence and interaction limits.
- WHO reports cardiovascular disease caused an estimated 19.8 million deaths in 2022 — about 32% of all global deaths — with heart attack and stroke accounting for 85% of that toll (WHO CVD fact sheet).
- In PREDIMED’s reanalysis, a Mediterranean eating pattern plus olive oil or nuts reduced the combined cardiovascular-event endpoint in 7,447 older, high-risk adults without prior cardiovascular disease. Individual heart-attack and mortality results were not significant. PREDIMED 2018.
- In 27 statin trials, each 1 mmol/L LDL-C reduction lowered major vascular events by about 21%; absolute benefit depends on baseline risk. CTT meta-analysis.
- A meta-analysis of 123 trials reported lower cardiovascular-event and mortality risk with blood-pressure treatment. Its original abstract was verified; full methods and financial declarations were not recovered. Lancet BP meta-analysis.
- Quitting smoking after coronary disease was associated with fewer deaths and events in observational evidence. Exercise-based cardiac rehabilitation reduced heart attacks and hospital admissions in trials; short-term mortality benefit was uncertain. Cochrane smoking review; Cochrane rehabilitation review.
Table of contents
- Evidence summary
- What heart disease is
- Selected diagnoses
- Prevention priorities
- Management after diagnosis
- Supplements with evidence
- Side effects
- Interactions
- What works and what does not
- Sources and funding notes
Evidence summary
| Claim | Best evidence | Funding / conflict trace | Strength |
|---|---|---|---|
| Many cardiovascular events can be prevented or delayed by controlling modifiable risks. | WHO identifies tobacco, unhealthy diet, obesity, inactivity, harmful alcohol use, air pollution, raised blood pressure, raised blood glucose, and raised blood lipids as major modifiable risks (World Health Organization). | WHO public-health guidance; page-specific financing and individual declarations are not supplied, and underlying financial chains were not fully traced. | Strong |
| Cardiovascular health is multidimensional. | AHA’s eight metrics cover diet, activity, inhaled nicotine exposure, sleep duration, BMI, lipids, glucose and blood pressure. This consensus scorecard is not a trial showing equal or additive benefit from each component (AHA Life’s Essential 8, AHA advisory). | Public/charitable author grants; Cheryl Anderson disclosed advisory/consulting relationships with WW and McCormick Science Foundation. Complete statement financing and ultimate backers were not traced. | Moderate |
| Mediterranean-style diets reduce major cardiovascular events in high-risk adults. | The reanalysis of 7,447 older high-risk adults without prior CVD found fewer combined events with Mediterranean patterns plus oil or nuts; separate heart-attack and mortality results were not significant (PREDIMED reanalysis). | Spanish/European public support, Fundación Mapfre and donated oil/nuts. Allocation deviations required adjusted reanalysis. Full original paper read; separate individual author financial forms remain inaccessible. (Primary source) | Moderate |
| Reducing saturated fat modestly lowers cardiovascular-event risk when replacement foods are appropriate. | The later 2020 Cochrane version found a 17% relative reduction in combined cardiovascular events, without a mortality benefit. Replacement-fat versus carbohydrate subgroup differences were not significant; refined and unrefined carbohydrates could not be separated (Cochrane saturated-fat review, Latest 2020 PubMed record). | WHO commissioned the update and provided grant/travel support to Hooper and Jimoh; university support also reported. Other authors reported no known interests. Included-study financing was not fully cleared. | Moderate |
| Higher physical activity is associated with lower cardiovascular and mortality risk. | A dose-response meta-analysis of 196 articles covering 94 cohorts and more than 30 million participants found higher non-occupational physical activity associated with lower cardiovascular disease and mortality risk (physical activity meta-analysis). | Public/charitable and scholarship support included MRC, UKCRC CEDAR, ERC, NHMRC, Gates Cambridge, NIHR, A*STAR and Brazilian grants. No conflicts declared; cohort finances were not fully traced. | Moderate |
| Smoking cessation after coronary disease reduces recurrent risk. | Quitting versus continuing smoking after coronary disease was associated with lower cardiovascular death (moderate certainty) and major events (low certainty). All included data were analysed observationally by quit status (Cochrane smoking cessation review). | BHF studentship, NIHR infrastructure/investigator/ARC/BRC and Oxford support. Named authors declared no interests; all included-study financial chains were not traced. | Moderate |
| Blood-pressure treatment reduces major cardiovascular events. | A Lancet systematic review of 123 studies and 613,815 participants found blood-pressure-lowering treatment reduces major cardiovascular disease events, coronary heart disease, stroke, heart failure, and all-cause mortality; its renal-failure result was not statistically significant across many baseline groups (Lancet BP meta-analysis). | NIHR and Oxford Martin School named in the original abstract. Full original methods, author conflicts and included-trial financing were not recovered. | Strong |
| LDL-cholesterol lowering reduces vascular events. | The Cholesterol Treatment Trialists’ individual-participant meta-analysis found statin LDL reduction lowered major vascular events by about 21% per 1 mmol/L LDL-C reduction (CTT meta-analysis). | Public/heart-foundation support for the review; most underlying trials were pharmaceutical-industry funded. Some investigators received company meeting reimbursements; Keech/Simes disclosed Solvay lecture honoraria. | Strong |
| Exercise-based cardiac rehabilitation improves outcomes after coronary events. | In coronary-disease trials, rehabilitation reduced heart attacks (high certainty) and all-cause admissions (moderate certainty) at 6–12 months. Mortality differences at that interval were uncertain; quality-of-life improvements were not uniform (Cochrane cardiac rehabilitation review). | Glasgow salary/NIHR infrastructure support. Oldridge disclosed included-study ESC/EAPC support; Thompson and Zwisler authored included studies. Trial funding chains were not fully traced. | Moderate |
| Better medication adherence is associated with fewer events and deaths. | Higher adherence was associated with lower pooled event, stroke and mortality risks. The antihypertensive-only cardiovascular-event estimate was not significant; healthy-adherer confounding and major heterogeneity limit causal interpretation (cardiovascular adherence meta-analysis). | Authors declared no support for the submitted work and no relevant financial/nonfinancial interests. Underlying-study financing not fully traced; observational design remains a limitation. | Moderate |
What heart disease is
“Heart disease” is an umbrella term, not one diagnosis. WHO classifies cardiovascular diseases as disorders of the heart and blood vessels, including coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, and venous thromboembolism (World Health Organization).
Risk-factor control is central to common atherosclerotic disease. Congenital, valve, rhythm and other diagnoses require their own care plans; they are not all prevented by reducing atherosclerosis. WHO states that cardiovascular disease caused an estimated 19.8 million deaths in 2022, about 32% of global deaths, with heart attack and stroke accounting for 85% of those deaths (World Health Organization).
Text version of infographic: Heart risk stack
| Item | Meaning |
|---|---|
| Nicotine exposure | Avoid tobacco, vaping and secondhand smoke; therapeutic nicotine-replacement decisions belong in a cessation plan. |
| Blood pressure | Measured and treated blood pressure is one of the best-supported risk levers. |
| LDL cholesterol | Lowering LDL cholesterol reduces major vascular events in large trial meta-analysis. |
| Lifestyle cluster | Diet, activity, sleep and measured risk factors inform cardiovascular health; their treatment effects differ, and the eight-metric framework does not prove an equal additive effect. |
Selected diagnoses and care priorities
| Type | What it means | Main prevention / management focus | Evidence caveat |
|---|---|---|---|
| Coronary heart disease | Narrowing or dysfunction of blood vessels supplying the heart muscle. | LDL-C, blood pressure, tobacco cessation, glucose control, antiplatelet/statin/other clinician-directed medicines, cardiac rehab after events. | Most supplement evidence targets risk markers, not hard coronary outcomes. |
| Heart attack / myocardial infarction | Heart muscle injury, usually from reduced blood flow. | Emergency care, secondary prevention medicines, rehab, smoking cessation, risk-factor control. | Do not substitute supplements for acute symptoms or prescribed secondary-prevention care. |
| Heart failure | The heart cannot pump or fill well enough for the body’s needs. | Guideline-directed medicines, salt/fluid guidance when prescribed, monitored exercise, symptom tracking, device/procedure care when indicated. | CoQ10 has adjunct evidence but is not a replacement for heart-failure medicines (Cochrane CoQ10 review). |
| Arrhythmias | Abnormal heart rhythm, including atrial fibrillation. | Diagnosis, rhythm/rate management, stroke prevention, electrolyte review, sleep-apnea evaluation when suspected. | High-dose omega-3 has been linked with atrial fibrillation signals in some trials, so rhythm history matters (NIH ODS omega-3 fact sheet). |
| Valve disease | Heart valves are narrowed or leaky. | Imaging follow-up, symptom monitoring, procedures when indicated. | Lifestyle supports overall risk but cannot “clean” or repair a structurally damaged valve. |
| Congenital heart disease | Heart structure differences present from birth. | Specialist follow-up, activity guidance, pregnancy planning when relevant. | Adult prevention principles still apply, but individualized cardiology care dominates. |
Prevention priorities
1. Use a dietary pattern, not a single “heart food”
AHA encourages Mediterranean-style and DASH patterns. PREDIMED tested a Mediterranean pattern with counseling plus oil or nuts in older high-risk adults. The later 2020 Cochrane review supports a modest reduction in combined events with sustained saturated-fat reduction, but not a mortality benefit or proven superiority of polyunsaturated-fat over carbohydrate replacement. It could not separate refined from unrefined carbohydrate (PREDIMED reanalysis, Cochrane saturated-fat review). AHA dietary-pattern framework.
PREDIMED evaluated an eating pattern with repeated counseling, not an isolated oil or nut supplement. Food substitutions should fit the whole diet; the saturated-fat review does not establish one universal ranking of every replacement food. PREDIMED; Cochrane review.
2. Plan regular activity and adapt it to health status
Higher nonoccupational physical activity was associated with lower cardiovascular incidence and mortality in the cohort meta-analysis; residual confounding remains. AHA’s general adult target is at least 150 minutes of moderate or 75 minutes of vigorous activity weekly. After diagnosis, adapt activity to symptoms and the clinical care plan (physical activity meta-analysis). AHA activity target.
3. Quit tobacco completely
WHO recommends stopping tobacco. Among people with coronary disease, Cochrane found quitting was associated with lower cardiovascular death and major events than continued smoking. Quit-status confounding limits the exact numerical effect, but this does not weaken the practical recommendation to quit (Cochrane smoking cessation review). WHO prevention guidance.
4. Measure and control blood pressure, lipids, and glucose
High blood pressure, raised lipids, and raised glucose are “intermediate risk factors” that can be measured and treated, and WHO explicitly lists drug treatment of hypertension, diabetes, and high blood lipids as necessary to reduce cardiovascular risk in people with those conditions (World Health Organization). Large trial meta-analyses support BP lowering and LDL lowering as hard-outcome interventions, not just lab-number changes (Lancet BP meta-analysis, CTT meta-analysis).
5. Sleep and stress: treat them as risk amplifiers
AHA added sleep duration to its cardiovascular-health score; adults generally need 7–9 hours. The advisory notes limited evidence that changing sleep duration or quality reduces incident cardiovascular disease. Psychological health and social support matter to care, but they are not proof that a stress supplement prevents heart events (AHA Life’s Essential 8, AHA advisory).
Text version of infographic: Prevention pyramid
| Item | Meaning |
|---|---|
| Foundation | Avoid tobacco, vaping and secondhand smoke; measure and treat abnormal BP, lipids and glucose with an individualized plan. |
| Daily pattern | Mediterranean-style food pattern, regular activity, adequate sleep, and body-weight support. |
| After diagnosis | Use cardiac rehabilitation and medication adherence systems. |
| Supplements | Use only for evidence-matched targets and interaction checks. |
Management after a diagnosis
Management depends on the diagnosis. After a coronary event, secondary prevention aims to reduce further events and preserve function. Exercise-based cardiac rehabilitation can include exercise, education and psychological support, with supervised or home-based formats. The Cochrane review supports heart-attack and admission benefits in coronary disease; it does not establish every program as the most underused intervention or prove the same effect in heart-failure-only patients (Cochrane cardiac rehabilitation review).
Taking prescribed medicines consistently is part of care. Higher cardiovascular medication adherence was associated with fewer events and deaths in observational studies, but healthy-adherer bias and major heterogeneity prevent treating the association as a randomized causal estimate (cardiovascular adherence meta-analysis).
| Management lever | What to do | Why it matters | When to escalate |
|---|---|---|---|
| Medication adherence | Agree a feasible medication schedule and refill plan with the care team; bring a current medicine and supplement list. | Adherence tracks with lower event and mortality risk (cardiovascular adherence meta-analysis). | Report side effects rather than stopping heart medicines abruptly. |
| Cardiac rehabilitation | Ask about rehabilitation eligibility after heart attack, stent, bypass or angina. The cited review is coronary-disease evidence and excluded heart-failure-only trials. | In CHD, heart-attack and all-cause-admission benefits were found at 6–12 months; mortality benefit at that interval was uncertain (Cochrane cardiac rehabilitation review). | New or worsening symptoms need clinical review; suspected heart-attack or stroke symptoms require immediate care (WHO symptom guidance). |
| Risk-factor tracking | Track blood pressure, clinician-selected lipids and glucose measures, weight and tobacco exposure. AHA uses non-HDL cholesterol and glucose/HbA1c in context; it does not require routine apoB testing for everyone. | WHO identifies raised BP, glucose and lipids as measurable risks (World Health Organization); AHA advisory explains its health metrics. | Rising symptoms or uncontrolled numbers despite adherence need medication review. |
| Lifestyle maintenance | Plan meals, movement, sleep, stress recovery, and social support as recurring systems. | AHA combines behavior and measured biology in a consensus score; psychosocial health supports care but is not itself one of the eight metrics (AHA advisory). | Depression, insomnia, pain, or breathlessness often need professional support. |
Supplements with evidence
Supplements should be matched to a measurable target and checked against medicines. “Natural” does not mean low-risk, and many supplement trials measure LDL, triglycerides, blood pressure, or symptoms rather than heart attacks or survival.| Supplement | Most plausible heart-related use | What evidence supports | What it does not prove | Funding / conflict trace |
|---|---|---|---|---|
| Omega-3 EPA/DHA | Triglyceride lowering; selected high-risk adjunct care under clinician guidance. | Cochrane found little/no effect of increased long-chain omega-3 on all-cause mortality or cardiovascular events overall, while NIH ODS notes high-dose EPA-only and mixed EPA+DHA trials have conflicting event results (Cochrane omega-3 review, NIH ODS omega-3 fact sheet). | Ordinary fish-oil capsules are not proven “heart insurance” for everyone. | Review support: WHO, NIHR infrastructure and UEA; authors declared none known. Its trial records identify Amarin-funded REDUCE-IT and donated products in ASCEND/VITAL. All trial financing was not fully traced. |
| CoQ10 | Adjunct in selected heart-failure patients; not a replacement for guideline medicines. | The review included 11 trials with 1,573 people with chronic heart failure. Mortality benefit rested on one 420-person trial, and admission benefit on two studies; certainty ranged from very low to moderate (Cochrane CoQ10 review). | It does not reliably lower blood pressure or prevent statin muscle symptoms for everyone (NCCIH CoQ10). | NIHR review infrastructure; authors declared no interests. Two included trials were partly manufacturer funded. Most treatment was oral; one trial used a nasal route. Review-level disclosures do not clear all trial finances. |
| Magnesium | Correct deficiency; modest BP support in some adults. | A meta-analysis of 34 double-blind placebo-controlled trials found median 368 mg/day magnesium for 3 months reduced systolic BP by about 2.00 mmHg and diastolic BP by about 1.78 mmHg (magnesium BP meta-analysis). | It is not a stand-alone hypertension treatment and is unsafe in significant kidney disease without supervision (NIH ODS magnesium fact sheet). | IU Health–IU School of Medicine Strategic Research Initiative support; authors declared no conflicts. Complete financing of all 34 included trials was not traced. |
| Soluble fiber / psyllium / beta-glucan | LDL-C lowering; these cited meta-analyses assessed lipid markers, not clinical glucose or weight benefits. | The 181-trial soluble-fiber review reported LDL-C reduction but graded that evidence very low certainty because of heterogeneity/bias. The 28-trial psyllium abstract reports moderate-certainty LDL-C reduction; its full original was not recovered (soluble fiber meta-analysis, psyllium meta-analysis). | Fiber does not replace statins or BP medicines in high-risk disease. | Soluble-fiber funding section says no study funding, while author disclosures acknowledge Isfahan University support; exact terms unexplained. Psyllium full disclosures and all trial finances were not recovered. |
| Plant sterols / stanols | LDL-C lowering through reduced intestinal cholesterol absorption. | The 124-study analysis found ~6–12% LDL-C reductions across 0.6–3.3 g/day. Formulation/food vehicle matter; the older 59-trial review excluded capsules/tablets (plant sterol meta-analysis, dose-response meta-analysis). | The narrative review, searching through January 2023, identified no randomized trial proving fewer heart attacks or strokes from sterols alone (plant sterol review). | Ras/Trautwein were Unilever employees; Jones reported food-company consulting. The 2023 review reported no external funding but two authors disclosed pharmaceutical fees/support. Underlying trial finances remain incompletely traced. |
| Garlic | Small improvements in BP/lipids in some trials. | A review published online 2025 (2026 issue) reported marker improvements across 108 trials. Only its abstract/grant record was accessible; full methods and disclosures remain unverified. NCCIH’s 2021 digest describes small or low-quality hypertension studies (garlic RCT meta-analysis, NCCIH hypertension digest). | Garlic does not substitute for anticoagulants, statins, or BP medicines. | Kerman University of Medical Sciences grant 401000378 indexed; full review conflicts and all underlying trial financing were not recovered. NCCIH is public guidance, not financial clearance. |
| Folate / folic acid | Correction of inadequate folate; stroke-prevention findings depend on population and folate/fortification context. | The 2016 meta-analysis found a stroke signal without a coronary benefit. The 2024 first-stroke review was null overall; a nonfortified-setting subgroup benefited. Regimens included folic acid alone and combinations (folic acid CVD meta-analysis, folic acid stroke meta-analysis). | It is not a broad heart-attack prevention pill and can mask B12 deficiency at high supplemental intakes (NIH ODS folate fact sheet). | The 2016 review was partly Metagenics funded; Frank Hu reported company research support/consultancy. The 2024 review declared no financial support or commercial/financial conflicts; underlying trials were not fully financially traced. |
Text version of infographic: Supplement evidence map
| Item | Meaning |
|---|---|
| Lipid-marker evidence | Psyllium/soluble fiber and sterols can lower LDL-C; certainty, formulation and clinical-outcome evidence differ. |
| Selected clinical adjunct | CoQ10 has heart-failure adjunct signals but is not primary therapy. |
| Mixed event evidence | Omega-3 evidence is strongest for triglycerides and mixed for event prevention. |
| Avoid hype | Cleanses, homeopathic heart remedies, and miracle blends should not be marketed as heart disease treatments. |
Risks and reported side effects
| Category | Reported effects | Important risks and uncertainties | Who needs extra caution | Source and limits |
|---|---|---|---|---|
| Prescription heart medicines, broad class warning | Adverse effects depend on the exact medicine and patient; this guide does not provide a complete class-by-class list. | Use the current product label and prescribing team for serious warnings, contraindications and monitoring. | People with new symptoms or complex care should seek medicine-specific advice. | Individual drug labeling and clinical review are required. Do not change prescribed medicines without advice. |
| Omega-3 EPA/DHA | Fishy aftertaste, burping, GI upset, loose stools. | Some 4 g/day long-term trials found more atrial fibrillation. Most studies summarized by NIH did not find clinically important bleeding; anticoagulant monitoring can still be appropriate. | Anticoagulant users, people with AF history, seafood allergy or planned procedures should discuss the specific product and dose. | NIH ODS omega-3 fact sheet |
| CoQ10 | Insomnia, digestive upset, nausea, diarrhea, appetite loss. | Possible warfarin interaction. Oncology concerns include preclinical radiation evidence and observational associations, not proof every chemotherapy or radiation regimen is impaired. | Warfarin or insulin users and people receiving cancer treatment should involve the prescribing team; pregnancy/lactation safety is not established here. | NCCIH CoQ10; MSKCC CoQ10 |
| Magnesium | Diarrhea, nausea and abdominal cramping can occur; several salts have laxative effects. | Dangerous hypermagnesemia in kidney impairment or excessive dosing. | Kidney disease, older adults with reduced renal function, people using magnesium-containing laxatives/antacids. | NIH ODS magnesium fact sheet |
| Soluble fiber / psyllium | Digestive symptoms can occur; take psyllium with adequate liquid and follow the product directions. | Psyllium requires adequate liquid, and swallowing difficulty or intestinal blockage needs medical review; altered medication absorption is possible. (MedlinePlus psyllium) | Swallowing disorders, bowel obstruction/strictures, people taking narrow-therapeutic-index medicines. | psyllium meta-analysis (lipids); AAFP interaction review; MedlinePlus directions |
| Plant sterols / stanols | Carotenoid levels can fall; digestive tolerability varies and no universal frequency is established here. | Contraindicated in sitosterolemia; hard long-term event-safety evidence is incomplete. | Avoid in sitosterolemia. Pediatric familial-hypercholesterolemia use is specialist care; pregnancy and long-term safety require individual advice. | plant sterol review |
| Garlic supplements | Oral odor, abdominal pain, gas, nausea or allergy can occur. | Bleeding risk, allergic reactions, severe skin burns with raw topical garlic. | Anticoagulant/antiplatelet users, surgery planning, pregnancy/lactation beyond food amounts. | NCCIH garlic |
| Folic acid | No universal adverse-effect frequency is established here; dose and formulation matter. | High folic acid can correct B12-related anemia while neurological injury continues. Methotrexate and seizure-medicine decisions depend on the clinical regimen. | B12 deficiency risk, cancer therapy, antiepileptic use, methotrexate use. | NIH ODS folate fact sheet |
Selected interactions and precautions
| Interacts with | Type | Severity | Mechanism | Action |
|---|---|---|---|---|
| Omega-3 × anticoagulants/antiplatelets | Supplement–drug | Use with caution | High doses may affect clotting, but most reviewed studies did not show clinically important bleeding; a universal interaction with every anticoagulant or antiplatelet is not established. | Tell clinician before high-dose omega-3, surgery, or dual antiplatelet/anticoagulant therapy (NIH ODS omega-3). |
| Omega-3 × atrial fibrillation history | Supplement–condition | Monitor / clinician-led | Some high-dose trials reported atrial fibrillation signals. | Avoid self-prescribing high-dose EPA/DHA with AF history (NIH ODS omega-3). |
| CoQ10 × warfarin | Supplement–drug | Use with caution / monitor INR | Case reports and reference guidance suggest an interaction; its direction and size are not reliably predictable. | Do not start or stop without INR plan (NCCIH CoQ10). |
| CoQ10 × insulin | Supplement–drug | Monitor | NCCIH reports a possible insulin interaction; this is not established for every blood-pressure or diabetes medicine. | Discuss use with the insulin prescriber; do not change treatment yourself (NCCIH CoQ10). |
| CoQ10 × chemotherapy/radiation | Supplement–treatment | Avoid unless oncology team approves | Reference concerns include an animal radiation model and clinical associations; they do not establish that every treatment becomes less effective. | Ask oncology team first (MSKCC CoQ10). |
| Magnesium × tetracycline/quinolone antibiotics or bisphosphonates | Supplement–drug | Separate doses | Mineral binding reduces drug absorption. | Separate by several hours per product-specific instructions (NIH ODS magnesium). |
| Magnesium × diuretics / PPIs | Drug–nutrient | Monitor | Loop/thiazide diuretics can increase magnesium loss; potassium-sparing diuretics reduce excretion. Prolonged PPIs can cause low magnesium. | Check magnesium when clinically indicated (NIH ODS magnesium). |
| Psyllium × selected oral medicines | Supplement–drug | Separate and monitor | AAFP’s older review discusses reduced carbamazepine/lithium absorption; MedlinePlus separately names digoxin, salicylates and nitrofurantoin. | Ask the pharmacist for medicine-specific timing. MedlinePlus gives 3-hour separation for its named drugs (AAFP interaction review; MedlinePlus psyllium). |
| Plant sterols × bile acid sequestrants | Supplement–drug | Limited evidence; professional review | The review does not recommend this combination because evidence is limited and sterol absorption may be reduced. | Discuss the combination with the lipid prescriber; no universal spacing rule is established here (plant sterol review). |
| Garlic × anticoagulants/aspirin and surgery | Supplement–drug | Use with caution; stop before surgery if advised | Surgical bleeding associations and platelet effects support caution; evidence does not quantify a causal risk for every medicine combination. | Disclose use before surgery or anticoagulant therapy (NCCIH garlic, dietary supplements and bleeding review). |
| Folic acid × methotrexate, seizure medicines or B12 deficiency | Supplement–drug / supplement–condition | Clinician-led | Cancer methotrexate and low-dose autoimmune regimens differ: prescribed folate may help with low-dose methotrexate. High intake can conceal B12-related anemia. | Use the prescribing team’s regimen; do not start, stop or withhold prescribed folate based on a general interaction list (NIH ODS folate). |
What works and what does not
| Claim | Verdict | Evidence | Key caveat |
|---|---|---|---|
| Mediterranean-style eating lowers heart-event risk in high-risk adults. | WORKS | PREDIMED reanalysis. | Older high-risk primary-prevention adults; combined endpoint benefit, individual MI/mortality uncertain. |
| Higher nonoccupational activity is associated with lower cardiovascular risk. | ASSOCIATION SUPPORTS ACTIVITY | Large dose-response cohort meta-analysis. | Confounding/reverse causality remain; adapt activity to symptoms and medical status. |
| Smoking cessation after CHD reduces recurrence risk. | WORKS | Cochrane quit-status evidence: moderate certainty for cardiovascular death, low for major events. | Reduction is not enough; complete cessation is the goal. |
| Blood pressure and LDL treatment reduce events. | WORKS | Large randomized-trial meta-analyses. | Targets and medicines are individualized. |
| Cardiac rehabilitation after coronary events improves outcomes. | WORKS | Cochrane: heart-attack/admission benefit at 6–12 months; mortality then uncertain. | Eligible coronary-disease care; home-based or supervised formats may be appropriate. |
| Ordinary fish oil prevents heart attacks in everyone. | DOESN’T, as a blanket claim | Cochrane found little/no overall event benefit. | High triglycerides and selected high-risk cases are different questions. |
| CoQ10 cures heart failure or replaces medicines. | DOESN’T | Cochrane shows adjunct signals only. | Use as add-on only after medication review. |
| Magnesium is a stand-alone BP medicine. | DOESN’T | Average BP effects are modest. | Useful when deficient; risky in kidney disease. |
| Plant sterols prevent heart attacks by themselves. | INSUFFICIENT EVIDENCE | LDL improves; the review searching through January 2023 identified no hard-outcome RCT. | A marker benefit is not the same as event proof. |
| Detoxes, cleanses, and homeopathy treat heart disease. | DOESN’T | NCCIH finds no compelling detox benefit; the 2002 homeopathy review found no convincing general efficacy, with methodological limits. | May delay proven care (NCCIH detoxes and cleanses, homeopathy systematic-review review). |
Text version of infographic: What to do this week
| Item | Meaning |
|---|---|
| Measurements | Use measured risk factors instead of guessing. |
| Food | Build a Mediterranean-style, minimally processed eating pattern. |
| Movement | Schedule activity adapted to health status, or formal cardiac rehabilitation when eligible. |
| Review | Bring all medicines and supplements to a clinician or pharmacist review. |
Frequently asked questions
Can heart disease be prevented?
Many cardiovascular events can be prevented or delayed by controlling modifiable risks including tobacco exposure, diet quality, physical inactivity, harmful alcohol use, air pollution exposure where possible, blood pressure, blood glucose, blood lipids, and weight (World Health Organization). Genetics, age, sex, environment, and access to care still matter, so prevention means lowering risk rather than guaranteeing immunity.
What is the best diet for heart disease prevention?
Mediterranean-style and DASH patterns are reasonable options in AHA guidance. PREDIMED supports a Mediterranean pattern in older high-risk adults, while sustained saturated-fat reduction modestly reduced combined events in Cochrane’s later 2020 review. Neither source ranks every diet or replacement food as universally best (PREDIMED reanalysis, Cochrane saturated-fat review). AHA diet framework.
Do supplements prevent heart attacks?
The supplements reviewed here have different targets and evidence limits. Omega-3 can reduce triglycerides but has little or no overall cardiovascular-event benefit in the cited synthesis; CoQ10 heart-failure findings rely on limited adjunct trials. Neither supports replacing prescribed prevention or rehabilitation (Cochrane omega-3 review, Cochrane CoQ10 review).
Is cardiac rehabilitation worth it?
For eligible people with coronary disease, rehabilitation can reduce heart attacks and admissions and may improve selected quality-of-life measures. Formats include home-based or supervised exercise, sometimes with education or psychological care. Short-term mortality benefit was uncertain in the cited review (Cochrane cardiac rehabilitation review).
What numbers should be tracked?
Track clinician-selected blood pressure, lipids and glucose measures, alongside weight, tobacco exposure and symptoms. AHA’s metrics include non-HDL cholesterol and HbA1c in context; they do not require apoB testing for everyone. Choose additional tests and monitoring with the care team (World Health Organization). AHA metrics.
What should make someone seek urgent medical care?
Chest pain or pressure, arm/jaw/back discomfort, sudden breathlessness or faintness can be heart-attack symptoms. Sudden facial or limb weakness, speech or vision difficulty can signal stroke. Seek immediate medical care for these symptoms; this is not an exhaustive emergency-symptom list. WHO symptom guidance.
Sources and funding notes
Research funding at a glance
10 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | URL | Funding / conflict note |
|---|---|---|
| World Health Organization CVD fact sheet | WHO CVD fact sheet | WHO intergovernmental guidance. Page-specific financing/author declarations not supplied; underlying studies not financially cleared. |
| AHA Life’s Essential 8 advisory | PubMed 35766027 | Public/charitable author grants; Cheryl Anderson disclosed WW/McCormick Science Foundation advisory/consulting ties. Consensus metric framework, not a product trial. |
| PREDIMED reanalysis | PubMed 29897866 | Public/regional Spanish and European funds, Fundación Mapfre and donated products from Hojiblanca, Patrimonio Comunal Olivarero, California Walnut Commission, Borges and Morella Nuts. Separate author financial forms remain inaccessible; allocation deviations limit interpretation. |
| Cochrane saturated-fat review | PubMed 32827219: later 2020 version | WHO grant/travel support to Hooper/Jimoh and university support. Other authors no known interests. Latest version gives 17% combined-event reduction; no mortality benefit. |
| Physical activity meta-analysis | PubMed 36854652 | MRC, UKCRC CEDAR, ERC, NHMRC, Gates Cambridge, NIHR, A*STAR and Brazilian grants. No conflicts declared; underlying cohorts not financially cleared. |
| Smoking cessation in CHD | PubMed 35938889 | BHF studentship; NIHR infrastructure/investigator/ARC/BRC and Oxford support. Authors declared no interests; quit-status data observational. |
| Blood-pressure lowering meta-analysis | PubMed 26724178 | NIHR/Oxford Martin School in original abstract. Full methods, conflicts and included-trial financing not recovered. |
| LDL statin meta-analysis | PubMed 22607822 | Review public/heart-foundation support; most underlying trials pharmaceutical funded. Company meeting reimbursements and Solvay lecture honoraria disclosed. |
| Cardiac rehabilitation Cochrane review | PubMed 34741536 | Glasgow salaries/NIHR infrastructure; included-study ESC/EAPC support and authorship ties disclosed. All trial finances not traced. |
| Medication adherence meta-analysis | PubMed 34821699 | Authors declared no work support or relevant financial/nonfinancial interests. Observational design, healthy-adherer bias and high heterogeneity remain. |
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.